How the vitamin D–breaking enzyme CYP24A1 works in different body tissues
Tissue-Specific Regulation and Effects of CYP24A1
Researchers will switch off the CYP24A1 enzyme in kidney or intestinal tissue in lab models to learn how those changes affect vitamin D, calcium balance, and kidney disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11369599 on NIH RePORTER |
What this research studies
This project uses specially engineered mice that allow scientists to turn off CYP24A1 only in the kidney or only in the intestine. The team will measure blood levels of active vitamin D, calcium, parathyroid hormone, and kidney function, and will model chronic kidney disease to see tissue-specific effects. They will compare how loss of CYP24A1 in each organ changes vitamin D signaling across the body and whether it causes harmful high calcium or worsened kidney injury. Findings aim to clarify whether targeting CYP24A1 in specific tissues could improve or harm mineral balance in people with kidney problems.
Who could benefit from this research
Good fit: People with chronic kidney disease, abnormal calcium or vitamin D levels, or known disorders of vitamin D metabolism would be the most relevant patient group for future clinical translation.
Not a fit: People without kidney disease or any calcium/vitamin D disorders are unlikely to see direct benefit from this basic research.
Why it matters
Potential benefit: If successful, this work could guide safer vitamin D-related treatments and better control of calcium and mineral balance in people with chronic kidney disease.
How similar studies have performed: Prior work has largely focused on the enzyme that makes active vitamin D (CYP27B1), so tissue-specific study of CYP24A1 is relatively novel though grounded in strong genetic and physiological evidence.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Wolf, Myles S — Weill Medical Coll of Cornell Univ
- Study coordinator: Wolf, Myles S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.